Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer

Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure

(2018) M. E. M. van der Noordaa et al.   ANNALS OF SURGICAL ONCOLOGY

Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial ( M inimally I nvasive C omplete R esponse A ssessment)

(2018) M.E.M. van der Noordaa et al.   BREAST

Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy

(2018) Alison U. Barron et al.   JAMA Surgery

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

(2018) Mette S van Ramshorst et al.   LANCET ONCOLOGY

Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study

(2017) Mette S. van Ramshorst et al.   EUROPEAN JOURNAL OF CANCER

Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

(2017) Gary H. Lyman et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery

(2017) Audree B. Tadros et al.   JAMA Surgery

Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases

(2016) Armando E. Giuliano et al.   ANNALS OF SURGERY

Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes

(2016) Emilia J. Diego et al.   ANNALS OF SURGICAL ONCOLOGY

Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?

(2016) Joerg Heil et al.   EUROPEAN JOURNAL OF CANCER

Routine use of standard breast MRI compared to axillary ultrasound for differentiating between no, limited and advanced axillary nodal disease in newly diagnosed breast cancer patients

(2016) T.J.A. van Nijnatten et al.   EUROPEAN JOURNAL OF RADIOLOGY

Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection

(2016) Abigail S. Caudle et al.   JOURNAL OF CLINICAL ONCOLOGY

Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer Patients

(2015) Mila Donker et al.   ANNALS OF SURGERY

Efficacy of physical examination, ultrasound, and ultrasound combined with fine-needle aspiration for axilla staging of primary breast cancer

(2015) Yu Feng et al.   BREAST CANCER RESEARCH AND TREATMENT

Radioactive seed localization in breast cancer treatment

(2015) N. N. Y. Janssen et al.   BRITISH JOURNAL OF SURGERY

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

(2015) Sara M. Tolaney et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer

(2014) Judy C. Boughey et al.   ANNALS OF SURGERY

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial

(2014) Mila Donker et al.   LANCET ONCOLOGY

Pre-chemotherapy 18F-FDG PET/CT upstages nodal stage in stage II–III breast cancer patients treated with neoadjuvant chemotherapy

(2013) Bas B. Koolen et al.   BREAST CANCER RESEARCH AND TREATMENT

Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer

(2013) Judy C. Boughey   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

(2013) Viviana Galimberti et al.   LANCET ONCOLOGY

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

(2013) Thorsten Kuehn et al.   LANCET ONCOLOGY

Comparison of the Diagnostic Value of FDG-PET/CT and Axillary Ultrasound for the Detection of Lymph Node Metastases in Breast Cancer Patients

(2012) Carolin Riegger et al.   ACTA RADIOLOGICA

Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND)

(2012) Oreste Gentilini et al.   BREAST

Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy

(2012) Bas B. Koolen et al.   BREAST CANCER RESEARCH AND TREATMENT

Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer

(2010) M. E. Straver et al.   BRITISH JOURNAL OF SURGERY

Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer

(2010) Laura S. Dominici et al.   CANCER

Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial

(2010) David N Krag et al.   LANCET ONCOLOGY

Impact of Micrometastases in the Sentinel Node of Patients With Invasive Breast Cancer

(2009) Nora M. Hansen et al.   JOURNAL OF CLINICAL ONCOLOGY

Micrometastases or Isolated Tumor Cells and the Outcome of Breast Cancer

(2009) Maaike de Boer et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER